EGFR-specific single-chain variable fragment antibody-conjugated Fe₃O₄/Au nanoparticles as an active MRI contrast agent for NSCLC.

ABSTRACT: Overexpression of epidermal growth factor receptor (EGFR) is closely associated with a poor prognosis in non-small cell lung cancer (NSCLC), thus making it a promising biomarker for NSCLC diagnosis. Here, we conjugated a single-chain antibody (scFv) targeting EGFR with Fe₃O₄/Au nanoparticles to form an EGFR-specific molecular MRI bioprobe (scFv@Fe₃O₄/Au) to better detect EGFR-positive NSCLC tumors in vivo. In vitro, we demonstrated that the EGFR-specific scFv could specifically deliver Fe₃O₄/Au to EGFR-positive NSCLC cells. In vivo experiments showed that the accumulation of scFv@Fe₃O₄/Au in tumor tissue was detectable by magnetic resonance imaging (MRI) at the indicated time points after systemic injection. The T2W signal-to-noise ratio (SNR) of EGFR-positive SPC-A1 tumors was significantly decreased after scFv@Fe₃O₄/Au injection, which was not observed in the tumors of mice injected with BSA@Fe₃O₄/Au. Furthermore, transmission electron microscopy (TEM) analysis showed the specific localization of scFv@Fe₃O₄/Au in the SPC-A1 tumor cell cytoplasm. Collectively, the results of our study demonstrated that scFv@Fe₃O₄/Au might be a useful probe for the noninvasive diagnosis of EGFP-positive NSCLC.

SUBMITTER: Lu Y 

PROVIDER: S-EPMC7902179 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature